Transformational Change in the Treatment of **PE**

<1.0%

all-cause mortality at **30-day** follow-up

Outcomes from the FLASH registry for the treatment of pulmonary embolism with the **FlowTriever®** system

INARI MEDICAL®



FLASH

FlowTriever® System
Percutaneous Pulmonary Embolectomy Clinical Registry Study

Largest prospective interventional registry of PE.

<1.0%
All-cause mortality at 30-day follow-up
N=734

Immediate Hemodynamic Improvement

800 patients enrolled

800 patients enrolled

Characteristic	n (%) or mean± SD
Age, years	61.2±14.6
Concomitant DVT	512 (65.0%)
Lytics contraindication	256 (32.1%)

Intermediate-risk and **high-risk PE patients** have the greatest risk of hemodynamic decompensation.[2]

Characteristic	n (%) or mean± SD
High-risk PE	63 (7.9%)
Intermediate-high risk	611 (76.7%)
Intermediate-low risk	59 (7.4%)
Intermediate risk unknown	64 (8.0%)
sPESI	1.6±1.1
Positive biomarker(s)†	720 (94.6%)
RV/LV ratio*	1.5±0.5

† elevated BNP and/or troponin

* CT or echo

Immediate hemodynamic improvement[1]

Mean PAP



Cardiac Index



*In patients with cardiac index <2.0 L/min/m² at baseline

Heart Rate



TPVR



Low mortality[1]

<1.0%

all-cause mortality at 30-day follow-up

n=734

Excellent safety results[1]

1.8% **major adverse events (MAEs)**

at 48-hours

Deliver transformational change in the treatment of PE with the **FlowTriever** system

Triever24®

INARI MEDICAL®

FLASH

FlowTriever® System
Percutaneous Pulmonary Embolectomy Clinical Registry Study

FLASH is the largest prospective interventional registry of PE evaluating patient results after treatment with the **FlowTriever** system.

LEARN MORE

References:
1. Toma, C., et al. Acute Outcomes for the Full US Cohort of the FLASH Mechanical Thrombectomy Registry in Pulmonary Embolism. EuroIntervention. 2022; Published online ahead of print September 2022.
2. Giri, J., et al. Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation. 2019 Nov 12;140(20):e774-e801.

Indications for Use:
The FlowTriever Retrieval/Aspiration System is indicated for:
- The non-surgical removal of emboli and thrombi from blood vessels.
- Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel.

The **FlowTriever** Retrieval/Aspiration System is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism. **Triever**® catheters are intended for use in treating clot in transit in the right atrium, but not in conjunction with FlowTriever catheters. The **FlowTriever**2 catheter is intended for use in the peripheral vasculature only.

Refer to IFU for warnings, precautions, and contraindications.

Caution:
Federal (USA) law restricts this device to sale by or on the order of a physician.

MM-01280_Rev A_EN_2022-09-16

INARI MEDICAL®

6001 Oak Canyon, Suite 100, Irvine, CA 92618 | InariMedical.com